Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Kevin Balthaser currently holds 29,500 shares of Aclaris Therapeutics, Inc. (ACRS), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Kevin Balthaser has been a net buyer of ACRS stock. They have purchased $75.0K and sold $23.6K worth of shares.
Kevin Balthaser's most recent insider trade was on Feb 1, 2026, when they sold 14,750 shares at $0.00 per share.
Kevin Balthaser serves as Executive at Aclaris Therapeutics, Inc. (ACRS). They have executed 30 insider transactions totaling $98.6K over their tenure at the company.
Kevin Balthaser holds the position of Executive at Aclaris Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 4 years and currently hold a stake valued at $0.
Kevin Balthaser has shown a buying trading pattern, with $75.0K in total purchases and $23.6K in total sales across all transactions. Their most recent activity indicates a tendency to accumulate shares.
The largest transaction by Kevin Balthaser was on Sep 6, 2023, when they purchased $75.0K worth of ACRS shares. This transaction involved 9,490 shares at $7.90 per share.
Kevin Balthaser currently owns 29,500 shares of Aclaris Therapeutics, Inc. (ACRS), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Kevin Balthaser's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Kevin Balthaser has 30 Form 4 filings on record as an insider at Aclaris Therapeutics, Inc..
Set alerts for Kevin Balthaser and 40,000+ other insiders.